Biopower Operatn Financials

BOPO

Source SEC Filings (10-K/10-Q) Updated May 31, 2023 Currency USD FYE November

This page shows Biopower Operatn (BOPO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BOPO FY2022 2026-04-22

BioPower’s reported business looks dominated by balance-sheet strain, with tiny operating assets carrying nearly $6.0M of obligations.

From FY2020 to FY2022, total liabilities climbed from $4.36M to $5.95M even as cash liquidity shrank from $96K in FY2021 to $825 and equity stayed deeply negative. That combination says reported financing and operating activity were not rebuilding the balance sheet; they were mainly offsetting ongoing deficits while immediate liquidity got thinner.

FY2021 shows the operating mismatch clearly: $175K of revenue sat against $461K of SG&A. Operating cash flow of -$204K broadly matched the loss-making pattern, so the problem was insufficient scale rather than a one-off working-capital swing.

By FY2022, liquidity-bearing assets were extremely thin: of just $14K in total assets, only $825 was cash. Retained losses had reached -$10.35M, which helps explain why a modest rise in shares outstanding did not repair negative equity.

Financial Health Signals

Financial Profile 0/100

Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Biopower Operatn's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$825

YoY-99.1%

5Y CAGR-44.1%

Biopower Operatn held $825 in cash against $0 in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

46M

YoY+1.4%

5Y CAGR+2.1%

Biopower Operatn had 46M shares outstanding in fiscal year 2022. This represents an increase of 1.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

BOPO Income Statement

Metric	FY22	FY21	FY20	FY19	FY15	FY14
Revenue	N/A	$175K	N/A	N/A	$13K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$461K	N/A	N/A	N/A	N/A
Operating Income	N/A	-$286K	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	$33K-68.8%	$106K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$441K-240.1%	-$130K0.0%	-$130K	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	$125K-49.3%	$247K+23.4%	$200K	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$51K	N/A	$403K+89.9%	$212K+40.3%	$151K	N/A	$201K
Operating Income	N/A	N/A	N/A	-$278K-912.8%	$34K-29.5%	$49K	N/A	-$201K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	-$244K-1755.0%	-$13K-1213.4%	$1K	N/A	-$244K
EPS (Diluted)	$-0.10	N/A	N/A	N/A	$0.00	N/A	N/A	N/A

BOPO Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY15	FY14
Total Assets	$14K-85.4%	$96K	$0	$0-100.0%	$32K-34.2%	$48K
Current Assets	N/A	N/A	N/A	N/A	$14K-12.2%	$16K
Cash & Equivalents	$825-99.1%	$96K	N/A	N/A	$1K-91.5%	$15K
Inventory	$13K	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$331	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.0M+8.1%	$5.5M+26.2%	$4.4M+3.1%	$4.2M+8.4%	$3.9M+82.2%	$2.1M
Current Liabilities	$6.0M+8.1%	$5.5M+26.2%	$4.4M+3.1%	$4.2M+8.4%	$3.9M+82.2%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$5.9M-9.8%	-$5.4M-24.0%	-$4.4M-3.1%	-$4.2M-9.3%	-$3.9M-84.9%	-$2.1M
Retained Earnings	-$10.3M-8.3%	-$9.6M-4.8%	-$9.1M-1.4%	-$9.0M-13.9%	-$7.9M-38.9%	-$5.7M

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Total Assets	$13K-1.0%	$13K-4.9%	$14K-76.8%	$61K-90.1%	$613K+168.4%	$228K+138.1%	$96K-47.1%	$181K
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	N/A	$135-83.6%	$825-94.5%	$15K-97.1%	$522K+6059.1%	$8K-91.2%	$96K-47.1%	$181K
Inventory	$13K0.0%	$13K0.0%	$13K0.0%	$13K0.0%	$13K	N/A	N/A	N/A
Accounts Receivable	$3310.0%	$3310.0%	$3310.0%	$3310.0%	$331-99.8%	$200K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.9M+5.1%	$6.6M+10.1%	$6.0M+9.5%	$5.4M-6.0%	$5.8M+2.6%	$5.6M+2.4%	$5.5M+0.7%	$5.5M
Current Liabilities	$6.9M+5.1%	$6.6M+10.1%	$6.0M+9.5%	$5.4M-6.0%	$5.8M+2.6%	$5.6M+2.4%	$5.5M+0.7%	$5.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$6.9M-5.1%	-$6.5M-10.1%	-$5.9M-10.4%	-$5.4M-4.0%	-$5.2M+4.4%	-$5.4M0.0%	-$5.4M-2.3%	-$5.3M
Retained Earnings	-$15.7M-43.3%	-$11.0M-6.1%	-$10.3M-5.5%	-$9.8M-2.5%	-$9.6M-0.1%	-$9.6M0.0%	-$9.6M-1.3%	-$9.4M

BOPO Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY15	FY14
Operating Cash Flow	N/A	-$204K	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	$9K+90.2%	$5K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	-$9K-90.2%	-$5K
Financing Cash Flow	N/A	$300K	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Operating Cash Flow	-$380+44.9%	-$690+99.0%	-$69K-134.8%	$199K-24.5%	$264K+401.5%	-$87K-2.6%	-$85K	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	$55K	N/A	N/A	N/A	$0	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BOPO Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY15	FY14
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-163.6%	N/A	N/A	N/A	N/A
Net Margin	N/A	-252.2%	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-459.8%	N/A	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	N/A	0.000.0	0.01
Debt-to-Equity	-1.00+0.0	-1.02-0.0	-1.000.0	-1.000.0	-1.01+0.0	-1.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-222.8%-236.6pp	13.9%-10.4pp	24.3%	N/A	N/A
Net Margin	N/A	N/A	N/A	-195.0%-189.6pp	-5.3%-5.9pp	0.6%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	-402.6%-400.4pp	-2.1%-2.7pp	0.5%	N/A	-134.7%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	-1.000.0	-1.000.0	-1.000.0	-1.01+0.1	-1.12-0.1	-1.04-0.0	-1.02+0.0	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$5.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Methes Energies MEIL

$10K

Plastec Technologies Ltd PLTYF

$3.2M

Mdwerks Inc MDWK

$15.4M

Blackwell 3D Construction BDCC

$13K

Gemz Corp GMZP

$490K

Frequently Asked Questions

What are Biopower Operatn's total assets?

Biopower Operatn (BOPO) had $14K in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does Biopower Operatn have outstanding?

Biopower Operatn (BOPO) had 46M shares outstanding as of fiscal year 2022.

What is Biopower Operatn's debt-to-equity ratio?

Biopower Operatn (BOPO) had a debt-to-equity ratio of -1.00 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Biopower Operatn's debt-to-equity ratio negative or unusual?

Biopower Operatn (BOPO) has negative shareholder equity of -$5.9M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Biopower Operatn?

Biopower Operatn (BOPO) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.